ADPT · Adaptive Biotechnologies Corp
Price
Snapshot
50 fields · last close| Market Cap | $4.57B |
| P/E | — |
| Float | 156.5M |
| Beta | 2.19 |
| Volatility | 54.7% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Mid cap |
| Macro sensitivity | Very High |
| Clavix score | 59 |
| Price | 27.92 |
| Change | −2.41% |
| Prev Close | 28.61 |
| Open | 28.55 |
| Day Low | 27.91 |
| Day High | 28.68 |
| Avg Vol | 2 |
| Avg $ Vol | $66.74M |
| 52W High | 28.72 |
| 52W Low | 12.00 |
| 52W Pos | 95.2% |
| From High | −2.79% |
| From Low | +132.67% |
| Max DD 1Y | −39.35% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +9.10% |
| SMA 50 | +14.90% |
| SMA 200 | +54.81% |
| RSI (14) | 73.9 |
| Vol 30D | 39.8% |
| Vol 90D | 60.6% |
| 1Y Range | 12–29 |
| Daily bars | 900 |
| Perf Week | +18.22% |
| Perf Month | +12.24% |
| Perf Quarter | +63.21% |
| Perf Half Y | +111.93% |
| Perf Year | +123.17% |
| Perf YTD | +75.49% |
| Prev Day | −2.41% |
| Clavix | C |
| Debt / Eq | 0.60 |
| Curr Ratio | 3.34 |
| Int Cover | -21.9× |
| FCF Margin | 65.3% |
| Rev Growth | +21.5% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 16 / 19 |
Clavix risk grade
regraded every trading dayADPT grades C, 59 of 100. Steadiest on Sector Resilience (60), most exposed on Price Stability (44, fragile). 0 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 16 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| ADPT | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 2.19 | 1.18 |
| Volatilityannualized | 54.7% | 29.6% |
| Max drawdown, past yearworst peak-to-trough fall | −39.3% | — |
| Typical daily movemedian absolute daily change | 2.04% | — |
| Days beyond ±3%of the last 252 sessions | 9036% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ADPT | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 2.19 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Moderate47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ADPT | |
|---|---|
| 1 week | +18.2% |
| 1 month | +12.2% |
| Year to date | +75.5% |
| 1 year | +123.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ADPT | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 21since 21 Jul |
| Average score0 most bearish, 100 most bullish | 59 |
| Bullish · bearisharticles above 60 · below 40 | 13 · 5 |
| Directionarticles whose tone is improving vs worsening | 13 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| ADPT | |
|---|---|
| Revenue growthyear over year | +21.5% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAn insider at Adaptive Biotechnologies, Francis Lo, sold 115,406 shares on September 16th at an average price of $28.06, for about $3.24 million in total. The sale reduced his position by 34.32%, though it was executed under a pre-set automatic selling schedule (a Rule 10b5-1 plan, which lets insiders arrange stock sales in advance so the timing can't be tied to any non-public information).
Adaptive Biotechnologies announced that NCCN (the National Comprehensive Cancer Network, which sets widely-used cancer treatment guidelines in the US) has updated its Multiple Myeloma guidelines to create a dedicated framework for routine MRD (minimal residual disease, i.e. testing for tiny remaining traces of cancer) assessment across the patient journey. The article body provides no further detail beyond that statement.
Adaptive Biotechnologies announced that updated NCCN cancer treatment guidelines for multiple myeloma now include a dedicated framework for routine MRD testing (which checks whether any cancer cells remain after treatment) and specifically name clonoSEQ as an FDA-cleared test for this purpose, with a 10⁻⁶ sensitivity threshold now preferred.
Adaptive Biotechnologies announced that updated NCCN Guidelines for multiple myeloma now specifically reference the company's clonoSEQ test as an FDA-cleared option for measuring minimal residual disease (MRD), the small number of cancer cells that can remain after treatment, and prefer the 10-6 sensitivity level (detecting one cancer cell per million) that clonoSEQ provides. The update establishes a framework for routine MRD testing across the multiple myeloma patient journey.
Bank of New York Mellon Corp reported purchasing a new stake in Adaptive Biotechnologies Corporation during the second quarter, acquiring 429,229 shares valued at approximately $9.207 million.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| QGEN | Qiagen NV | B+ | $8.93B | 21.82 | 0.60 | Compare |
| BRKR | Bruker Corp | C | $9.35B | — | 1.25 | Compare |
| TXG | 10X Genomics Inc | C- | $9.98B | — | 2.04 | Compare |
| RGEN | Repligen Corp | B- | $9.98B | 240.33 | 1.14 | Compare |
| AVTR | Avantor Inc | B- | $10.50B | — | 0.97 | Compare |
| TECH | Bio-Techne Corp | B | $11.35B | 62.40 | 1.30 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $13.27B | — | 1.41 | Compare |
| TEM | Tempus AI Inc | D- | $14.05B | — | 2.33 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.